An investigation for investors in NASDAQ:RIGL shares was announced over potential breaches of fiduciary duties by certain officers and directors at Rigel Pharmaceuticals.
Investors who purchased shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Rigel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
On October 20, 2016, Rigel Pharmaceuticals, Inc. reported results from the second FIT phase 3 study and the long-term open-label extension study for Fostamatinib in adult chronic/persistent immune thrombocytopenia (ITP). Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) declined to as low as $1.95 per share on October 20, 2016.
On November 3, 2016, NASDAQ:RIGL shares closed at $2.50 per share.
Those who purchased NASDAQ:RIGL shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego